Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

FDA panel for Vascepa means likely delay
Amarin Corp. plc (NASDAQ:AMRN) said it expects FDA to extend the PDUFA date for Vascepa icosapent ethyl to late December from Sept. 28 after the agency scheduled